Skip to main content
SpringerLink
Log in

Autografting

Second autologous transplant with cyclosporin/interferon α-induced graft versus host disease for patients who have failed first-line consolidation

  • Original Article
  • Published:
Bone Marrow Transplantation Submit manuscript

Summary:

The prognosis for patients with non-Hodgkin's lymphoma (NHL) and advanced Hodgkin's disease (HD) who relapse following autologous transplant is poor. We report on a pilot study designed to evaluate the feasibility of using Cyclosporin A and interferon α to induce autologous GVHD following a second autologous transplant for relapsed lymphoma. In all, 10 patients entered the study with median age 46.5 years. Diagnosis was NHL (n=7) or Hodgkin's lymphoma (n=3). All had relapsed from a prior autologous transplant. The second transplant was well tolerated by all patients. Histological changes consistent with cutaneous GVHD developed in 30% of patients at a median of 22.5 days from transplant and settled spontaneously in all cases. Five patients have died (four from progressive disease) at a median 7 months from second transplant. Five patients are still alive and in complete remission at a median of 20 months from transplant. Median overall survival for the group is 13.5 months and median relapse-free survival has not been reached at 42 months. This is a well-tolerated regimen for use in this poor-risk group of patients with lymphoma. The overall survival and event-free survival are encouraging, however further studies are necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Vose JM, Bierman PJ, Anderson JR et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80: 2142–2148.

    CAS  PubMed  Google Scholar 

  2. Shamash J, Lee SM, Radford JA et al. Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. Ann Oncol 2000; 11: 715–719.

    Article  CAS  PubMed  Google Scholar 

  3. Vandenberghe E, Pearce R, Taghipour G et al. Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. J Clin Oncol 1997; 15: 1595–1600.

    Article  CAS  PubMed  Google Scholar 

  4. De Lima M, van Besien KW, Giralt SA et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 19: 121–127.

    Article  CAS  PubMed  Google Scholar 

  5. Tsai T, Goodman S, Saez R et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 1997; 20: 859–863.

    Article  CAS  PubMed  Google Scholar 

  6. Jones RJ, Ambinder RF, Piantadosi S, Santos GW . Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–653.

    CAS  PubMed  Google Scholar 

  7. Hood AF, Vogelsang GB, Black LP et al. Acute graft-vs-host disease. Development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987; 123: 745–750.

    Article  CAS  PubMed  Google Scholar 

  8. Hess AD, Thoburn CJ . Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease. Immunol Rev 1997; 157: 111–123.

    Article  CAS  PubMed  Google Scholar 

  9. Noga SJ, Horwitz L, Kim H et al. Interferon-gamma potentiates the antitumor effect of cyclosporine-induced autoimmunity. J Hematother 1992; 1: 75–84.

    Article  CAS  PubMed  Google Scholar 

  10. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.

    CAS  PubMed  Google Scholar 

  11. Reynolds C, Ratanatharathorn V, Adams P et al. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 2001; 27: 801–807.

    Article  CAS  PubMed  Google Scholar 

  12. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–1073.

    Article  CAS  PubMed  Google Scholar 

  13. Gale RP, Champlin RE . How does bone-marrow transplantation cure leukaemia? Lancet 1984; 2: 28–30.

    Article  CAS  PubMed  Google Scholar 

  14. Glazier A, Tutschka PJ, Farmer ER, Santos GW . Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med 1983; 158: 1–8.

    Article  CAS  PubMed  Google Scholar 

  15. Bryson JS, Jennings CD, Caywood BE, Kaplan AM . Induction of a syngeneic graft-versus-host disease-like syndrome in DBA/2 mice. Transplantation 1989; 48: 1042–1047.

    Article  CAS  PubMed  Google Scholar 

  16. Fischer AC, Beschorner WE, Hess AD . Requirements for the induction and adoptive transfer of cyclosporine-induced syngeneic graft-versus-host disease. J Exp Med 1989; 169: 1031–1041.

    Article  CAS  PubMed  Google Scholar 

  17. Hess AD, Fischer AC, Horwitz L et al. Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease. J Immunol 1994; 153: 400–411.

    CAS  PubMed  Google Scholar 

  18. Shinozawa T, Beschorner WE, Hess AD . The thymus and prolonged administration of cyclosporine. Irreversible immunopathologic changes associated with autologous pseudo-graft-versus-host disease. Transplantation 1990; 50: 106–111.

    Article  CAS  PubMed  Google Scholar 

  19. Beschorner WE, Ren H, Phillips J et al. Prevention of syngeneic graft-versus-host disease by recovery of thymic microenvironment after cyclosporine. Transplantation 1991; 52: 668–674.

    Article  CAS  PubMed  Google Scholar 

  20. Hess AD, Horwitz L, Beschorner WE, Santos GW . Development of graft-vs-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 1985; 161: 718–730.

    Article  CAS  PubMed  Google Scholar 

  21. Geller RB, Esa AH, Beschorner WE et al. Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 1989; 74: 1165–1171.

    CAS  PubMed  Google Scholar 

  22. Hess AD, Bright EC, Thoburn C et al. Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood 1997; 89: 2203–2209.

    CAS  PubMed  Google Scholar 

  23. Bryson JS, Jennings CD, Lowery DM et al. Rejection of an MHC class II negative tumor following induction of murine syngeneic graft-versus-host disease. Bone Marrow Transplant 1999; 23: 363–372.

    Article  CAS  PubMed  Google Scholar 

  24. Miura Y, Ueda M, Zeng W H et al. Induction of autologous graft-versus-host disease with cyclosporin A after peripheral blood stem cell transplantation: analysis of factors affecting induction. J Allergy Clin Immunol 2000; 106: S51–S57.

    Article  CAS  PubMed  Google Scholar 

  25. Jones RJ, Vogelsang GB, Hess AD et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; 1: 754–757.

    Article  CAS  PubMed  Google Scholar 

  26. Ratanatharathorn V, Uberti J, Karanes C et al. Phase I study of alpha-interferon augmentation of cyclosporine-induced graft versus host disease in recipients of autologous bone marrow transplantation. Bone Marrow Transplant 1994; 13: 625–630.

    CAS  PubMed  Google Scholar 

  27. Pati AR, Godder KT, Abhyankar SH et al. Cyclosporine-induced autologous graft-versus-host disease following autologous blood stem cell transplantation for lymphoma. Bone Marrow Transplant 1996; 17: 1081–1083.

    CAS  PubMed  Google Scholar 

  28. Gryn J, Johnson E, Goldman N et al. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon. Bone Marrow Transplant 1997; 19: 221–226.

    Article  CAS  PubMed  Google Scholar 

  29. Vogelsang G, Bitton R, Piantadosi S et al. Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial. Bone Marrow Transplant 1999; 24: 637–640.

    Article  CAS  PubMed  Google Scholar 

  30. Baron F, Gothot A, Salmon JP et al. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. Br J Haematol 2000; 111: 745–753.

    CAS  PubMed  Google Scholar 

  31. Miura Y, Thoburn CJ, Bright EC et al. Characterization of the T-cell repertoire in autologous graft-versus-host disease (GVHD): evidence for the involvement of antigen-driven T-cell response in the development of autologous GVHD. Blood 2001; 98: 868–876.

    Article  CAS  PubMed  Google Scholar 

  32. Wu DY, Goldschneider I . Tolerance to cyclosporin A-induced autologous graft-versus-host disease is mediated by a CD4+CD25+ subset of recent thymic emigrants. J Immunol 2001; 166: 7158–7164.

    Article  CAS  PubMed  Google Scholar 

  33. Branson K, Chopra R, Kottaridis PD et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20: 4022–4031.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Guys Hospital, Guys and St Thomas' NHS Trust, London, UK

    M Streetly, M Kazmi, D Radia & S A Schey

  2. Glan Clywd Hospital, Rhyl, Denbighshire, UK

    C Hoyle

Authors
  1. M Streetly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Kazmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Radia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Hoyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S A Schey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S A Schey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Streetly, M., Kazmi, M., Radia, D. et al. Second autologous transplant with cyclosporin/interferon α-induced graft versus host disease for patients who have failed first-line consolidation. Bone Marrow Transplant 33, 1131–1135 (2004). https://doi.org/10.1038/sj.bmt.1704484

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704484

  • Springer Nature Limited

Keywords

This article is cited by

Search

Navigation